BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33952468)

  • 1. A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.
    Ishigami I; Shuwari N; Kaminade T; Mizuguchi H; Sakurai F
    Anticancer Res; 2021 May; 41(5):2431-2440. PubMed ID: 33952468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
    Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
    Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
    Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
    Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
    Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression.
    Koo BH; Kim Y; Je Cho Y; Kim DS
    Eur J Pharmacol; 2015 Oct; 764():413-423. PubMed ID: 26187313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
    Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
    PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
    Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
    Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization of Non-Small Cell Lung Cancer Cells by Inhibition of TGF-β1 Signaling With SB431542 Is Dependent on p53 Status.
    Zhao Y; Wang L; Huang Q; Jiang Y; Wang J; Zhang L; Tian Y; Yang H
    Oncol Res; 2016; 24(1):1-7. PubMed ID: 27178816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GP73 promotes epithelial-mesenchymal transition and invasion partly by activating TGF-β1/Smad2 signaling in hepatocellular carcinoma.
    Yang Y; Liu Q; Li Z; Zhang R; Jia C; Yang Z; Zhao H; Ya S; Mao R; Ailijiang T; Bao Y; Zhang H
    Carcinogenesis; 2018 Jul; 39(7):900-910. PubMed ID: 29365054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
    Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
    Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
    Bhagyaraj E; Ahuja N; Kumar S; Tiwari D; Gupta S; Nanduri R; Gupta P
    Cell Cycle; 2019 Dec; 18(24):3589-3602. PubMed ID: 31739702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma.
    Zhang C; Chen B; Jiao A; Li F; Sun N; Zhang G; Zhang J
    BMC Cancer; 2018 Nov; 18(1):1179. PubMed ID: 30486878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ERK1/2 Signaling Impairs the Promoting Effects of TGF-β1 on Hepatocellular Carcinoma Cell Invasion and Epithelial-Mesenchymal Transition.
    Liu L; Li N; Zhang Q; Zhou J; Lin L; He X
    Oncol Res; 2017 Nov; 25(9):1607-1616. PubMed ID: 28492136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
    Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
    PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
    Fransvea E; Angelotti U; Antonaci S; Giannelli G
    Hepatology; 2008 May; 47(5):1557-66. PubMed ID: 18318443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells enhance the metastasis of 3D-cultured hepatocellular carcinoma cells.
    Liu C; Liu Y; Xu XX; Guo X; Sun GW; Ma XJ
    BMC Cancer; 2016 Jul; 16():566. PubMed ID: 27475525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6.
    He AD; Xie W; Song W; Ma YY; Liu G; Liang ML; Da XW; Yao GQ; Zhang BX; Gao CJ; Xiang JZ; Ming ZY
    Sci Rep; 2017 Jun; 7(1):3989. PubMed ID: 28638139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
    Ungerleider N; Han C; Zhang J; Yao L; Wu T
    Mol Carcinog; 2017 Apr; 56(4):1302-1311. PubMed ID: 27862334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.